Business Context and Reporting Period
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on cardiovascular medicines. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company recently achieved a major milestone with the FDA approval of CARDAMYST™ (etripamil) nasal spray on December 12, 2025, for the treatment of paroxysmal supraventricular tachycardia (PSVT). Commercialization began in the U.S. in January 2026. The Company is also advancing a Phase 3 clinical trial for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $238 | $0 |
| Net Loss | $(26,066) | $(20,761) |
| Net Loss Per Share (Basic & Diluted) | $(0.20) | $(0.31) |
| Cash, Cash Equivalents, and Short-Term Investments | $184,216 | $N/A |
| Net Cash Used in Operating Activities | $(16,053) | $(13,952) |
| Total Liabilities | $157,685 | $71,792 |
| Shareholders' Equity | $36,049 | $(6,123) |
Note: Q1 2025 equity data is derived from the Statement of Shareholders' Equity balance as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Generation: The Company recorded $238,000 in product revenue from CARDAMYST sales in Q1 2026, compared to zero in Q1 2025, marking the start of commercial operations.
- Commercial Expenses: Increased by 52.4% to $15.8 million (from $10.4 million) due to the deployment of a national sales force and launch activities.
- Interest Expense: Surged by 342.3% to $4.1 million, primarily driven by $3.1 million in non-cash interest accretion on a new royalty financing obligation.
- Debt Structure: A new Royalty Financing Obligation of $78.1 million was recorded following the sale of royalty rights for $75.0 million in January 2026. This significantly increased total liabilities.
- Investing Activities: The Company invested $80.0 million in short-term investments during the quarter, compared to net redemptions in the prior year.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash, cash equivalents, and short-term investments of $184.2 million are sufficient to fund operations for at least the next 12 months.
- Outlook: The Company expects to continue incurring significant operating losses as it scales commercialization for PSVT and advances the AFib-RVR Phase 3 trial (first patient enrollment expected in H2 2026).
- Strategic Developments:
- Entered a new Controlled Equity Offering (ATM) agreement with Cantor Fitzgerald on May 13, 2026.
- Corxel Pharmaceuticals transferred Greater China rights for CARDAMYST to Everest Medicines in March 2026.
- Risks: Key risks include the uncertainty of commercial adoption rates for CARDAMYST, the success of the AFib-RVR clinical trial, reliance on single-source suppliers, and the impact of the royalty financing obligation on future cash flows.
Investor Verification Checklist
- Commercial Trajectory: Verify the rate of CARDAMYST adoption and whether revenue growth accelerates beyond the initial $238k in Q1.
- Royalty Obligation Impact: Assess the sensitivity of the $78.1 million royalty liability to changes in sales forecasts, as this drives significant non-cash interest expense.
- Cash Burn Rate: Monitor the net cash used in operating activities ($16.1M in Q1) against the $184.2M cash balance to confirm the 12-month runway.
- AFib-RVR Trial Progress: Track enrollment timelines for the Phase 3 AFib-RVR study, which is critical for future valuation.
- Equity Dilution: Review subsequent warrant exercises and potential sales under the new ATM agreement for dilution effects.